• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性出血性毛细血管扩张症中表型的循环因素

Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.

作者信息

Shovlin Claire L

机构信息

NHLI Cardiovascular Sciences, Imperial Centre for Translational and Experimental Medicine, Imperial College London London, UK ; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust London, UK.

出版信息

Front Genet. 2015 Apr 9;6:101. doi: 10.3389/fgene.2015.00101. eCollection 2015.

DOI:10.3389/fgene.2015.00101
PMID:25914716
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4391027/
Abstract

Hereditary hemorrhagic telangiectasia (HHT) is mechanistically and therapeutically challenging, not only because of the molecular and cellular perturbations that generate vascular abnormalities, but also the modifications to circulatory physiology that result, and are likely to exacerbate vascular injury. First, most HHT patients have visceral arteriovenous malformations (AVMs). Significant visceral AVMs reduce the systemic vascular resistance: supra-normal cardiac outputs are required to maintain arterial blood pressure, and may result in significant pulmonary venous hypertension. Secondly, bleeding from nasal and gastrointestinal telangiectasia leads to iron losses of such magnitude that in most cases, diet is insufficient to meet the 'hemorrhage adjusted iron requirement.' Resultant iron deficiency restricts erythropoiesis, leading to anemia and further increases in cardiac output. Low iron levels are also associated with venous and arterial thromboses, elevated Factor VIII, and increased platelet aggregation to circulating 5HT (serotonin). Third, recent data highlight that reduced oxygenation of blood due to pulmonary AVMs results in a graded erythrocytotic response to maintain arterial oxygen content, and higher stroke volumes and/or heart rates to maintain oxygen delivery. Finally, HHT-independent factors such as diet, pregnancy, sepsis, and other intercurrent illnesses also influence vascular structures, hemorrhage, and iron handling in HHT patients. These considerations emphasize the complexity of mechanisms that impact on vascular structures in HHT, and also offer opportunities for targeted therapeutic approaches.

摘要

遗传性出血性毛细血管扩张症(HHT)在发病机制和治疗方面都具有挑战性,这不仅是因为导致血管异常的分子和细胞紊乱,还因为由此引起的循环生理改变,而且这些改变可能会加剧血管损伤。首先,大多数HHT患者存在内脏动静脉畸形(AVM)。显著的内脏AVM会降低体循环血管阻力:需要超常的心输出量来维持动脉血压,这可能导致显著的肺静脉高压。其次,鼻腔和胃肠道毛细血管扩张引起的出血导致铁流失量很大,以至于在大多数情况下,饮食不足以满足“因出血而调整的铁需求量”。由此产生的缺铁会限制红细胞生成,导致贫血,并进一步增加心输出量。低铁水平还与静脉和动脉血栓形成、因子VIII升高以及血小板对循环5-羟色胺(血清素)的聚集增加有关。第三,最近的数据表明,由于肺AVM导致的血液氧合降低会引发分级红细胞增多反应以维持动脉血氧含量,并通过增加每搏输出量和/或心率来维持氧输送。最后,与HHT无关的因素,如饮食、妊娠、败血症和其他并发疾病,也会影响HHT患者的血管结构、出血和铁代谢。这些因素强调了影响HHT血管结构的机制的复杂性,同时也为靶向治疗方法提供了机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7e/4391027/8e162c39c2a7/fgene-06-00101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7e/4391027/1fece3c0195f/fgene-06-00101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7e/4391027/8e162c39c2a7/fgene-06-00101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7e/4391027/1fece3c0195f/fgene-06-00101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e7e/4391027/8e162c39c2a7/fgene-06-00101-g002.jpg

相似文献

1
Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症中表型的循环因素
Front Genet. 2015 Apr 9;6:101. doi: 10.3389/fgene.2015.00101. eCollection 2015.
2
Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.遗传性出血性毛细血管扩张症中报告的心脏表型强调了心律失常、贫血及其治疗带来的负担,但提示心肌梗死发生率降低。
Int J Cardiol. 2016 Jul 15;215:179-85. doi: 10.1016/j.ijcard.2016.04.006. Epub 2016 Apr 7.
3
[Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].[贝伐单抗:遗传性出血性毛细血管扩张症治疗的新突破]
Rev Med Interne. 2015 Sep;36(9):623-5. doi: 10.1016/j.revmed.2014.11.004. Epub 2015 Jan 13.
4
Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes.遗传性出血性毛细血管扩张症与妊娠:潜在不良事件及妊娠结局
Int J Womens Health. 2017 May 26;9:373-378. doi: 10.2147/IJWH.S131585. eCollection 2017.
5
Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis.遗传性出血性毛细血管扩张症患者脑动静脉畸形的患病率和特征:系统评价和荟萃分析。
J Neurosurg. 2017 Aug;127(2):302-310. doi: 10.3171/2016.7.JNS16847. Epub 2016 Oct 21.
6
Cardiac and Hemodynamic Manifestations of Hereditary Hemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症的心脏和血流动力学表现
Int J Angiol. 2022 Jul 9;31(2):75-82. doi: 10.1055/s-0042-1745842. eCollection 2022 Jun.
7
Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.遗传性出血性毛细血管扩张症(HHT)中因子VIII升高:与静脉血栓栓塞的关联
Thromb Haemost. 2007 Nov;98(5):1031-9.
8
Pulmonary gas exchange in hereditary hemorrhagic telangiectasia patients with liver arteriovenous malformations.遗传性出血性毛细血管扩张症伴肝动静脉畸形患者的肺气体交换。
Respir Res. 2019 Jul 4;20(1):137. doi: 10.1186/s12931-019-1106-y.
9
Hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症
Handb Clin Neurol. 2015;132:185-97. doi: 10.1016/B978-0-444-62702-5.00013-5.
10
Cerebral vascular malformations in hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症中的脑血管畸形。
J Neurosurg. 2014 Jan;120(1):87-92. doi: 10.3171/2013.10.JNS122402. Epub 2013 Nov 15.

引用本文的文献

1
How I treat bleeding in hereditary hemorrhagic telangiectasia.我如何治疗遗传性出血性毛细血管扩张症的出血。
Blood. 2024 Aug 29;144(9):940-954. doi: 10.1182/blood.2023021765.
2
Anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia: A scoping review.遗传性出血性毛细血管扩张症的抗凝和抗血小板治疗:范围综述。
Thromb Res. 2023 Jun;226:150-155. doi: 10.1016/j.thromres.2023.04.017. Epub 2023 May 3.
3
Update on pulmonary arteriovenous malformations.肺动静脉畸形更新。

本文引用的文献

1
Hypoxaemia, sport and polycythaemia: a case from Imperial College London.低氧血症、运动与红细胞增多症:来自伦敦帝国理工学院的一个病例
Thorax. 2015 Jun;70(6):601-3. doi: 10.1136/thoraxjnl-2014-206381. Epub 2015 Apr 8.
2
Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.因子V莱顿突变和高FVIII水平与接受辅助他莫昔芬治疗的乳腺癌女性发生静脉血栓栓塞(VTE)的风险增加相关——一项前瞻性单中心病例对照研究的结果
Eur J Intern Med. 2015 Jan;26(1):63-7. doi: 10.1016/j.ejim.2014.12.015. Epub 2015 Jan 12.
3
J Bras Pneumol. 2023 May 1;49(2):e20220359. doi: 10.36416/1806-3756/e20220359. eCollection 2023.
4
Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症的抗凝和抗血小板治疗的安全性、耐受性和有效性。
J Thromb Haemost. 2023 Jan;21(1):26-36. doi: 10.1016/j.jtha.2022.09.003. Epub 2022 Dec 22.
5
Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症的突变和表型特征。
Blood. 2020 Oct 22;136(17):1907-1918. doi: 10.1182/blood.2019004560.
6
Hereditary haemorrhagic telangiectasia: A disease not to be forgotten during the COVID-19 pandemic.遗传性出血性毛细血管扩张症:一种在新冠疫情期间不应被遗忘的疾病。
J Thromb Haemost. 2020 Jul;18(7):1799-1801. doi: 10.1111/jth.14885.
7
Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia.低血清结合珠蛋白和血涂片提示血管内溶血导致遗传性出血性毛细血管扩张症中的严重贫血。
Haematologica. 2019 Apr;104(4):e127-e130. doi: 10.3324/haematol.2018.205682. Epub 2018 Oct 18.
8
The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症相关肺动脉高压的临床特征及长期预后
Pulm Circ. 2018 Apr-Jun;8(2):2045894018759918. doi: 10.1177/2045894018759918. Epub 2018 Feb 26.
9
Embolisation of PAVMs reported to improve nosebleeds by a subgroup of patients with hereditary haemorrhagic telangiectasia.据报告,肺动静脉畸形栓塞术可改善遗传性出血性毛细血管扩张症患者亚组的鼻出血症状。
ERJ Open Res. 2016 Apr 29;2(2). doi: 10.1183/23120541.00035-2016. eCollection 2016 Apr.
10
Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?铁剂治疗会加重某些遗传性出血性毛细血管扩张症患者的鼻出血吗?
Laryngoscope. 2016 Nov;126(11):2468-2474. doi: 10.1002/lary.25959. Epub 2016 Apr 23.
Pulmonary arteriovenous malformations.
肺动静脉畸形
Am J Respir Crit Care Med. 2014 Dec 1;190(11):1217-28. doi: 10.1164/rccm.201407-1254CI.
4
Iron deficiency, ischaemic strokes, and right-to-left shunts: From pulmonary arteriovenous malformations to patent foramen ovale?缺铁、缺血性中风与右向左分流:从肺动静脉畸形到卵圆孔未闭?
Intractable Rare Dis Res. 2014 May;3(2):60-4. doi: 10.5582/irdr.2014.01008.
5
AltitudeOmics: rapid hemoglobin mass alterations with early acclimatization to and de-acclimatization from 5260 m in healthy humans.海拔高度组学:健康人在5260米高度早期适应和脱适应过程中血红蛋白质量的快速变化
PLoS One. 2014 Oct 1;9(10):e108788. doi: 10.1371/journal.pone.0108788. eCollection 2014.
6
Diagnosis and treatment of iron deficiency in patients with heart failure: expert position paper from French cardiologists.心力衰竭患者缺铁的诊断与治疗:法国心脏病专家的专家立场文件
Arch Cardiovasc Dis. 2014 Oct;107(10):563-71. doi: 10.1016/j.acvd.2014.07.049. Epub 2014 Sep 17.
7
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.羧基麦芽糖铁长期静脉治疗对有症状心力衰竭合并缺铁患者的有益作用†
Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31.
8
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.氨甲环酸治疗遗传性出血性毛细血管扩张症患者鼻出血:一种罕见病的欧洲交叉对照试验。
J Thromb Haemost. 2014 Sep;12(9):1494-502. doi: 10.1111/jth.12654. Epub 2014 Jul 29.
9
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.氨甲环酸治疗遗传性出血性毛细血管扩张症鼻出血的双盲安慰剂对照交叉 IIIB 期研究。
Thromb Res. 2014 Sep;134(3):565-71. doi: 10.1016/j.thromres.2014.06.012. Epub 2014 Jun 16.
10
Identification of erythroferrone as an erythroid regulator of iron metabolism.鉴定红系铁调素为铁代谢的红系调节因子。
Nat Genet. 2014 Jul;46(7):678-84. doi: 10.1038/ng.2996. Epub 2014 Jun 1.